1095 related articles for article (PubMed ID: 26501191)
1. Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids.
Huang L; Holtzinger A; Jagan I; BeGora M; Lohse I; Ngai N; Nostro C; Wang R; Muthuswamy LB; Crawford HC; Arrowsmith C; Kalloger SE; Renouf DJ; Connor AA; Cleary S; Schaeffer DF; Roehrl M; Tsao MS; Gallinger S; Keller G; Muthuswamy SK
Nat Med; 2015 Nov; 21(11):1364-71. PubMed ID: 26501191
[TBL] [Abstract][Full Text] [Related]
2. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
3. Metabolic Rewiring by Loss of Sirt5 Promotes Kras-Induced Pancreatic Cancer Progression.
Hu T; Shukla SK; Vernucci E; He C; Wang D; King RJ; Jha K; Siddhanta K; Mullen NJ; Attri KS; Murthy D; Chaika NV; Thakur R; Mulder SE; Pacheco CG; Fu X; High RR; Yu F; Lazenby A; Steegborn C; Lan P; Mehla K; Rotili D; Chaudhary S; Valente S; Tafani M; Mai A; Auwerx J; Verdin E; Tuveson D; Singh PK
Gastroenterology; 2021 Nov; 161(5):1584-1600. PubMed ID: 34245764
[TBL] [Abstract][Full Text] [Related]
4. Personalizing pancreatic cancer organoids with hPSCs.
Zhang HC; Kuo CJ
Nat Med; 2015 Nov; 21(11):1249-51. PubMed ID: 26540385
[No Abstract] [Full Text] [Related]
5. Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer.
Qian W; Li J; Chen K; Jiang Z; Cheng L; Zhou C; Yan B; Cao J; Ma Q; Duan W
Life Sci; 2018 Sep; 208():253-261. PubMed ID: 30053447
[TBL] [Abstract][Full Text] [Related]
6. Commitment and oncogene-induced plasticity of human stem cell-derived pancreatic acinar and ductal organoids.
Huang L; Desai R; Conrad DN; Leite NC; Akshinthala D; Lim CM; Gonzalez R; Muthuswamy LB; Gartner Z; Muthuswamy SK
Cell Stem Cell; 2021 Jun; 28(6):1090-1104.e6. PubMed ID: 33915081
[TBL] [Abstract][Full Text] [Related]
7. Pancreatic cancer-derived organoids - a disease modeling tool to predict drug response.
Frappart PO; Walter K; Gout J; Beutel AK; Morawe M; Arnold F; Breunig M; Barth TF; Marienfeld R; Schulte L; Ettrich T; Hackert T; Svinarenko M; Rösler R; Wiese S; Wiese H; Perkhofer L; Müller M; Lechel A; Sainz B; Hermann PC; Seufferlein T; Kleger A
United European Gastroenterol J; 2020 Jun; 8(5):594-606. PubMed ID: 32213029
[TBL] [Abstract][Full Text] [Related]
8. NFATc1 Links EGFR Signaling to Induction of Sox9 Transcription and Acinar-Ductal Transdifferentiation in the Pancreas.
Chen NM; Singh G; Koenig A; Liou GY; Storz P; Zhang JS; Regul L; Nagarajan S; Kühnemuth B; Johnsen SA; Hebrok M; Siveke J; Billadeau DD; Ellenrieder V; Hessmann E
Gastroenterology; 2015 May; 148(5):1024-1034.e9. PubMed ID: 25623042
[TBL] [Abstract][Full Text] [Related]
9. Loss of P53 Function Activates JAK2-STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival.
Wörmann SM; Song L; Ai J; Diakopoulos KN; Kurkowski MU; Görgülü K; Ruess D; Campbell A; Doglioni C; Jodrell D; Neesse A; Demir IE; Karpathaki AP; Barenboim M; Hagemann T; Rose-John S; Sansom O; Schmid RM; Protti MP; Lesina M; Algül H
Gastroenterology; 2016 Jul; 151(1):180-193.e12. PubMed ID: 27003603
[TBL] [Abstract][Full Text] [Related]
10. Quantification of fluorophore distribution and therapeutic response in matched in vivo and ex vivo pancreatic cancer model systems.
Solanki A; King D; Thibault G; Wang L; Gibbs SL
PLoS One; 2020; 15(2):e0229407. PubMed ID: 32097436
[TBL] [Abstract][Full Text] [Related]
11. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma.
Dhayat SA; Mardin WA; Seggewiß J; Ströse AJ; Matuszcak C; Hummel R; Senninger N; Mees ST; Haier J
PLoS One; 2015; 10(11):e0143755. PubMed ID: 26606261
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine Enhances Kras-MEK-Induced Matrix Metalloproteinase-10 Expression Via Histone Acetylation in Gemcitabine-Resistant Pancreatic Tumor-initiating Cells.
Shimizu K; Nishiyama T; Hori Y
Pancreas; 2017 Feb; 46(2):268-275. PubMed ID: 28060183
[TBL] [Abstract][Full Text] [Related]
14. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
15. CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer.
Colbert LE; Petrova AV; Fisher SB; Pantazides BG; Madden MZ; Hardy CW; Warren MD; Pan Y; Nagaraju GP; Liu EA; Saka B; Hall WA; Shelton JW; Gandhi K; Pauly R; Kowalski J; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Curran WJ; Landry JC; Maithel SK; Yu DS
Cancer Res; 2014 May; 74(10):2677-87. PubMed ID: 24626090
[TBL] [Abstract][Full Text] [Related]
16. Establishment and Characterization of a New Pancreatic Ductal Adenocarcinoma Cell Line Capan-26.
Zalyte E; Dedonyte V; Kurlinkus B; Sileikis A; Schemmer P; Valius M
Anticancer Res; 2021 Mar; 41(3):1401-1406. PubMed ID: 33788731
[TBL] [Abstract][Full Text] [Related]
17. KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy.
Kullmann F; Hartmann A; Stöhr R; Messmann H; Dollinger MM; Trojan J; Fuchs M; Hollerbach S; Harder J; Troppmann M; Kutscheidt A; Endlicher E
Oncology; 2011; 81(1):3-8. PubMed ID: 21894049
[TBL] [Abstract][Full Text] [Related]
18. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
[TBL] [Abstract][Full Text] [Related]
19. Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer.
Junttila MR; Devasthali V; Cheng JH; Castillo J; Metcalfe C; Clermont AC; Otter DD; Chan E; Bou-Reslan H; Cao T; Forrest W; Nannini MA; French D; Carano R; Merchant M; Hoeflich KP; Singh M
Mol Cancer Ther; 2015 Jan; 14(1):40-7. PubMed ID: 25376606
[TBL] [Abstract][Full Text] [Related]
20. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
